# Tourmaline Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tourmaline-bio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.tourmalinebio.com/
- Total disclosed funding: $101M
- Latest round: Series A (May 2, 2023)
- Investors on record: 3

## About

Based in New York, US, and founded in 2021, Tourmaline Bio, Inc. operates a biotechnology company that focuses on developing medicines for life-altering immune diseases. The company was co-founded by Sandeep Kulkarni, MD (CEO), and Caley Castelein, MD. In January 2024, Tourmaline Bio, Inc. raised USD 150 million in a private placement, selling 4.62 million shares at USD 32.50 per share on the Nasdaq Global Select Market.

The company's primary focus lies in the development of Tourmaline's anti-IL-6 antibody (TOUR006) for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). Its portfolio includes medications designed to address immune diseases that can have a profound impact on individuals, providing medical professionals with effective solutions to help cure their patients.

## Funding rounds

- Series A, May 2, 2023, $101M — Cowen Investment Management, TCG Crossover Management, Deep Track Capital

## Investors

- Cowen Investment Management — Series A
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series A
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series A